| Overactive Bladder
Gemtesa vs Myrbetriq
Side-by-side clinical, coverage, and cost comparison for overactive bladder.Deep comparison between: Gemtesa vs Myrbetriq with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsMyrbetriq has a higher rate of injection site reactions vs Gemtesa based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Myrbetriq but not Gemtesa, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Gemtesa
Myrbetriq
At A Glance
Oral
Once daily
Beta-3 adrenergic agonist
Oral
Once daily
Beta-3 adrenergic agonist
Indications
- Overactive Bladder
- Overactive Bladder
- Neurogenic detrusor overactivity
Dosing
Overactive Bladder 75 mg tablet orally once daily with or without food; swallow whole with a glass of water, or crush and mix with approximately 15 mL of applesauce and take immediately with water.
Overactive Bladder 25 mg orally once daily (starting dose), alone or in combination with solifenacin succinate 5 mg once daily; may increase to 50 mg once daily after 4-8 weeks.
Neurogenic detrusor overactivity Pediatric patients >=3 years: weight-based once-daily dosing; patients <35 kg use MYRBETRIQ Granules (24-64 mg/day depending on weight); patients >=35 kg use MYRBETRIQ 25 mg once daily (or MYRBETRIQ Granules 6 mL/48 mg once daily), increasing to maximum 50 mg (or 10 mL/80 mg) after 4-8 weeks.
Contraindications
- Known hypersensitivity to vibegron or any components of GEMTESA
- Known hypersensitivity to mirabegron or any inactive ingredient of the tablet or oral suspension
Adverse Reactions
Most common (>=2%) Headache, nasopharyngitis, diarrhea, nausea, upper respiratory tract infection, urinary tract infection, bronchitis
Serious Urinary retention
Postmarketing Urinary retention, angioedema of the face and larynx, hypersensitivity reactions (urticaria, pruritus, rash, drug eruption), eczema, constipation
Most common (>2%) Hypertension, nasopharyngitis, urinary tract infection, headache
Serious Urinary retention, angioedema, atrial fibrillation
Postmarketing Atrial fibrillation, nausea, constipation, diarrhea, dizziness, headache, angioedema of the face/lips/tongue/larynx, urinary retention, pruritus, confusion, hallucinations, insomnia, anxiety
Pharmacology
Vibegron is a selective human beta-3 adrenergic receptor agonist; activation of the beta-3 adrenergic receptor increases bladder capacity by relaxing the detrusor smooth muscle during bladder filling.
Mirabegron is a beta-3 adrenergic receptor agonist that relaxes detrusor smooth muscle during the bladder storage phase by activating beta-3 AR, thereby increasing bladder capacity.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Gemtesa
- Covered on 5 commercial plans
- PA (5/12) · Step Therapy (9/12) · Qty limit (11/12)
Myrbetriq
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (9/12) · Qty limit (10/12)
UnitedHealthcare
Gemtesa
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Myrbetriq
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Gemtesa
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (2/3)
Myrbetriq
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Gemtesa.
No savings programs available for Myrbetriq.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
GemtesaView full Gemtesa profile
MyrbetriqView full Myrbetriq profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.